Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Porter’s Five Forces Analysis
- Potential for New Entrants (Low to Moderate)
- Bargaining Power of Suppliers (Moderate to High)
- Bargaining Power of Buyers (Moderate)
- Threat of Substitute Products or Services (Moderate to High)
- Industry Rivalry (High)
- Medical Coding and Billing Challenges in Neurology
- Step Therapy
- Medicare Cuts
- Coding errors
- Use of Modifiers
- Documentation
- Coverage and Prior Authorization
- Compliance and Audits
- Reimbursement Rate and Denials
- Physician Payment Challenges
- Evaluation and Management (E/M) - Bill the Correct Level of Care
- Negotiating Contracts
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Growing Geriatric Population with Neurological Disorders
- Increasing Global Incidence of Neurological Disorders
- Government and NGO Initiatives in Creating Awareness
- Research Initiatives in Neurology
- Market Restraints
- Patent Expirations of Branded Drugs and Emergence of Generics
- Adverse Side Effects
- High Cost of Drug Development
Chapter 4 Emerging Trends and Pipeline Analysis
- Emerging Trends
- Precision Medicine in Neurological Disorders
- Gene Therapy for Neurological Disorders
- Neurodegeneration and Stem Cell Therapy
- Nanotechnology in Neuroscience
- Virtual Reality and Digital Therapeutics
- Conclusion
- Pipeline Analysis
Chapter 5 Regulatory Landscape
- Overview
- Cross-Disciplinary Value Story
- High-Quality Patient-Reported Outcome Data
- Impact of New EU and the U.S. Legislation
- Conclusion
Chapter 6 Market Segmentation Analysis
- Segmental Breakdown
- Market Analysis by Disease Indication
- Parkinson’s Disease
- Alzheimer’s Disease
- Psychotic Disorders
- Epileptic Disorder
- Autism Spectrum Disorder
- Brain Tumor
- Multiple Sclerosis
- Others
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Company Share Analysis of Anti-Parkinson’s Drugs
- Company Share Analysis of Alzheimer’s Disease Drugs
- Company Share Analysis of Antipsychotic Drugs
- Company Share Analysis of Anti-Epileptic Drugs
- Company Share Analysis of ASD Therapeutics
- Company Share Analysis of Brain Tumor Therapeutics
- Company Share Analysis of Multiple Sclerosis Therapeutics
List of Tables
Summary Table: Global Neurology Market, by Disease Indication, Through 2029
Table 1: Navigate New Neurology-related Codes
Table 2: Adverse Side Effects of Some Neurological Drugs
Table 3: List of Some Clinical Trial Drugs for Parkinson’s Disease in Phase 3 and 4
Table 4: List of Some Clinical Trial Drugs for Alzheimer’s Disease in Phase 3 and 4
Table 5: List of Some Clinical Trial Drugs for Epilepsy Disorder in Phase 3 and 4
Table 6: List of Some Clinical Trial Drugs for Autism Spectrum Disorders in Phase 3 and 4
Table 7: List of Some Clinical Trial Drugs for Brain Tumors in Phase 3 and 4
Table 8: List of Some Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4
Table 9: Global Neurology Market, by Disease Indication, Through 2029
Table 10: Global Neurology Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2029
Table 11: Global Neurology Market for Anti-Parkinson’s Drugs, by Region, Through 2029
Table 12: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2029
Table 13: Global Neurology Market for Alzheimer Drugs, by Region, Through 2029
Table 14: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2029
Table 15: Some Novel Antipsychotic Drug Targets and Therapeutic Characteristics
Table 16: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2029
Table 17: Global Neurology Market for Anti-Epileptic Drugs, by Drug Class, Through 2029
Table 18: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2029
Table 19: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2029
Table 20: Global Neurology Market for ASD Therapeutics, by Region, Through 2029
Table 21: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2029
Table 22: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2029
Table 23: FDA Approved DMTs
Table 24: Global Neurology Market for Multiple Sclerosis Therapeutics, by Region, Through 2029
Table 25: Global Neurology Market for Other Disease Therapeutics, by Region, Through 2029
Table 26: Global Neurology Market, by Region, Through 2029
Table 27: North American Neurology Market, by Disease Indication, Through 2029
Table 28: North American Neurology Market, by Country, Through 2029
Table 29: U.S. Neurology Market, by Disease Indication, Through 2029
Table 30: Canadian Neurology Market, by Disease Indication, Through 2029
Table 31: Mexican Neurology Market, by Disease Indication, Through 2029
Table 32: European Neurology Market, by Disease Indication, Through 2029
Table 33: European Neurology Market, by Country, Through 2029
Table 34: German Neurology Market, by Disease Indication, Through 2029
Table 35: U.K. Neurology Market, by Disease Indication, Through 2029
Table 36: French Neurology Market, by Disease Indication, Through 2029
Table 37: Spanish Neurology Market, by Disease Indication, Through 2029
Table 38: Italian Neurology Market, by Disease Indication, Through 2029
Table 39: Rest of European Neurology Market, by Disease Indication, Through 2029
Table 40: Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 41: Asia-Pacific Neurology Market, by Country, Through 2029
Table 42: Chinese Neurology Market, by Disease Indication, Through 2029
Table 43: Japanese Neurology Market, by Disease Indication, Through 2029
Table 44: Indian Neurology Market, by Disease Indication, Through 2029
Table 45: Rest of Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 46: Rest of the World Neurology Market, by Disease Indication, Through 2029
Table 47: Key Companies in Alzheimer’s Generic Drug Market
Table 48: Key Companies in Alzheimer’s Branded Drug Market
Table 49: Global Ranking of Leading Manufacturers of ASD Drugs
Table 50: Information Sources in this Report
Table 51: Abbreviations Used in the Global Neurology Market Report
Table 52: AbbVie Inc.: Company Snapshot
Table 53: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 54: AbbVie Inc.: Product Portfolio
Table 55: AbbVie Inc: News/Key Developments, 2023 and 2024
Table 56: Alpha Cognition: Company Snapshot
Table 57: Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 58: Alpha Cognition.: Product Portfolio
Table 59: Alpha Cognition: News/Key Developments, 2024
Table 60: Biogen.: Company Snapshot
Table 61: Biogen: Financial Performance, FY 2022 and 2023
Table 62: Biogen: Product Portfolio
Table 63: Biogen: News/Key Developments, 2023 and 2024
Table 64: Boehringer Ingelheim International GmbH: Company Snapshot
Table 65: Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 66: Boehringer Ingelheim International GmbH: Product Portfolio
Table 67: Boehringer Ingelheim International GmbH: News/Key Developments, 2024
Table 68: Bristol-Myers Squibb Co.: Company Snapshot
Table 69: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 70: Bristol-Myers Squibb Co.: Product Portfolio
Table 71: Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 72: Eisai Co. Ltd.: Company Snapshot
Table 73: Eisai Co. Ltd..: Financial Performance, FY 2022 and 2023
Table 74: Eisai Co. Ltd.: Product Portfolio
Table 75: Eisai Co. Ltd.: News/Recent Developments, 2023 and 2024
Table 76: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 77: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 78: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 79: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 80: H. Lundbeck A/S: Company Snapshot
Table 81: H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
Table 82: H. Lundbeck A/S: Product Portfolio
Table 83: H. Lundbeck A/S: News/Key Developments, 2021 and 2024
Table 84: Lilly: Company Snapshot
Table 85: Lilly: Financial Performance, FY 2022 and 2023
Table 86: Lilly: Product Portfolio
Table 87: Lilly: News/Key Developments, 2024
Table 88: Merck & Co. Inc.: Company Snapshot
Table 89: Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 90: Merck & Co. Inc.: Product Portfolio
Table 91: Merck & Co. Inc.: News/Key Developments, 2023
Table 92: Novartis AG: Company Snapshot
Table 93: Novartis AG: Financial Performance, FY 2022 and 2023
Table 94: Novartis AG: Product Portfolio
Table 95: Novartis AG: News/Key Developments, 2022 and 2023
Table 96: Otsuka Holdings Co. Ltd.: Company Snapshot
Table 97: Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 98: Otsuka Holdings Co. Ltd.: Product Portfolio
Table 99: Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
Table 100: Sanofi: Company Snapshot
Table 101: Sanofi: Financial Performance, FY 2022 and 2023
Table 102: Sanofi: Product Portfolio
Table 103: Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 104: Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 105: Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 106: Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
Table 107: UCB S.A.: Company Snapshot
Table 108: UCB S.A.: Financial Performance, FY 2022 and 2023
Table 109: UCB S.A.: Product Portfolio
Table 110: UCB S.A.: News/Key Developments, 2024
List of Figures
Summary Figure: Global Neurology Market Share, by Disease Indication, 2023
Figure 1: Porter’s Five Forces Analysis of the Neurology Market
Figure 2: Market Dynamics of Neurology Market
Figure 3: Breakdown of People Aging 65 or Older with Alzheimer’s Dementia, 2024
Figure 4: Global Burden of Conditions Affecting the Nervous System, 2021
Figure 5: Pipeline Analysis of Some Neurological drugs, by Phases, 2024
Figure 6: Global Neurology Market Share, by Disease Indication, 2023
Figure 7: Global Neurology Market Share for Anti-Parkinson’s Drugs, by Drug Class, 2023
Figure 8: Global Neurology Market Share for Anti-Parkinson’s Drugs, by Region, 2023
Figure 9: Global Neurology Market Share for Alzheimer Drugs, by Mechanism of Action, 2023
Figure 10: Global Neurology Market Share for Alzheimer Drugs, by Region, 2023
Figure 11: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2023
Figure 12: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2023
Figure 13: Prevalence of Mental Illnesses in U.S. Adult Populations, 2023
Figure 14: Global Neurology Market Share for Anti-Epileptic Drugs, by Drug Class, 2023
Figure 15: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2023
Figure 16: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2023
Figure 17: Global Neurology Market Share for ASD Therapeutics, by Region, 2023
Figure 18: Global Market Share of Brain and Central Nervous System Cases, both Sexes, by WHO Region, 2022
Figure 19: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2023
Figure 20: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2023
Figure 21: Prevalence of Multiple Sclerosis Cases in Select Countries, 2019
Figure 22: Global Neurology Market Share for Multiple Sclerosis Therapeutics, by Region, 2023
Figure 23: Global Neurology Market Share for Other Disease Therapeutics, by Region, 2023
Figure 24: Global Neurology Market Share, by Region, 2023
Figure 25: North American Neurology Market, by Disease Indication, 2021-2029
Figure 26: North American Neurology Market Share, by Country, 2023
Figure 27: European Neurology Market, by Disease Indication, 2021-2029
Figure 28: European Neurology Market Share, by Country, 2023
Figure 29: Asia-Pacific Neurology Market, by Disease Indication, 2021-2029
Figure 30: Asia-Pacific Neurology Market Share, by Country, 2023
Figure 31: Rest of the World Neurology Market, by Disease Indication, 2021-2029
Figure 32: Share of Major Players in Anti-Parkinson’s Drugs Market, 2023
Figure 33: Share of Major Players in Antipsychotic Drugs Market, 2023
Figure 34: Share of Major Players in Anti-Epileptic Drugs Market, 2023
Figure 35: Share of Major Players in Brain Tumor Therapeutics Market, 2023
Figure 36: Share of Major Players in Multiple Sclerosis Therapeutics Market, 2023
Figure 37: AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 38: AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 39: Biogen: Revenue Share, by Business Unit, FY 2023
Figure 40: Biogen: Revenue Share, by Country/Region, FY 2023
Figure 41: Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 42: Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 43: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 44: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 45: Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 46: Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023
Figure 47: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 48: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 49: H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023
Figure 50: H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023
Figure 51: Lilly: Revenue Share, by Business Unit, FY 2023
Figure 52: Lilly: Revenue Share, by Country/Region, FY 2023
Figure 53: Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54: Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 55: Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 56: Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 57: Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 58: Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 59: Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 60: Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 61: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 62: UCB S.A.: Revenue Share, by Business Unit, FY 2023
Figure 63: UCB S.A.: Revenue Share, by Country/Region, FY 2023